quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·160d
NEWSRelease
NanoViricides Inc. logo

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NNVC· NanoViricides Inc.
Health Care
Original source

Companies

  • NNVC
    NanoViricides Inc.
    Health Care

Recent analyst ratings

  • Dec 16UpdateAlliance Global Partners-

Related

  • NEWS3d
    Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
  • NEWS17d
    Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
  • NEWS23d
    Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
  • NEWS44d
    NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
  • SEC65d
    SEC Form 10-Q filed by NanoViricides Inc.
  • NEWS70d
    MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
  • NEWS72d
    Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
  • NEWS80d
    NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022